Market access for PD-1 inhibitors: where are we now?
This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.
Fill in your details to watch this webinar
The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.
- Key emerging trends on market access
- How agencies are approaching assessments for melanoma, lung cancer and RCC
- Specific review of PD-1 testing in health technology assessments
- Explore the move in the treatment towards combination therapies
Duration: 45 minutes. Available to watch on demand.
Ideal viewing: Global, regional, and affiliate market access and HEOR teams involved in pricing strategy and pricing and reimbursement decisions can benefit from watching this on-demand webinar. Please share this with your colleagues.